Targeting integrins for the control of tumour angiogenesis

Expert Opinion on Investigational Drugs

Volumn 14, Issue 12, 2005, Pages 1475-1486

  Akalu, Abebe ^a   Cretu, Alexandra ^a   Brooks, Peter C ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; Extracellular matrix; Integrin antagonists; Matrix immobilised cryptic ECM epitopes

Indexed keywords

ALPHA4 BETA7 ANTIGEN ANTAGONIST; ANASTELLIN; ANGIOGENESIS INHIBITOR; ANTISENSE OLIGONUCLEOTIDE; BLOCKING AGENT; CANSTATIN; DISINTEGRIN; ENDOREPELIN; ENDOSTATIN; FASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTEGRIN; INTEGRIN ANTAGONIST; INTEGRIN ANTIBODY; LIGAND; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY LM 609; MONOCLONAL ANTIBODY M200; OBTUSTATIN; PEPTIDE; PROTEIN ANTIBODY; RESTIN; RETINA S ANTIGEN; SEMAPHORIN; SULFONAMIDE; THROMBOSPONDIN 1; TUMSTATIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERY LATE ACTIVATION ANTIGEN 4 ANTAGONIST; VERY LATE ACTIVATION ANTIGEN 5 ANTAGONIST;

CLINICAL TRIAL; DRUG DESIGN; DRUG TARGETING; EXTRACELLULAR MATRIX; HUMAN; LIGAND BINDING; NONHUMAN; PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; INTEGRINS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 28644439936     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.14.12.1475     Document Type: Review

References (101)

1. RAFII S, LYDEN D, BENEZRA R, HATTORI K, HEISSIG B: Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy. Nat. Rev. Caner. (2002) 2(11):826-835.
2. SUNDERKOTTER C, STEINBRINK K, GOEBELER M, BHARDWAJ R, SORG C: Macrophages and angiogenesis. J. Leuk. Biol. (1994) 55(3):410-422.
3. RUF W, SEFTOR EA, PETROVAN RJ et al.: Differential role of tissue factor pathway inhibitors 1 and 2 in melanoma vasculogenic mimicry. Cancer Res. (2003) 63(17):5381-5389.
4. VAN DER SCHAFT DW, SEFTOR RE, SEFTOR EA et al.: Effects of angiogenesis inhibitors on vascular network formation by human endothelial and melanoma cells. J. Natl. Cancer Inst. (2004) 96(19):1473-1477.
5. STUPACK DG, CHERESH DA: Integrins and angiogenesis. Curr. Opin. Devl. Biol. (2004) 64:207-238.
6. RISAU W: Mechanisms of angiogenesis. Nature (1997) 386(6626):671-674.
7. WIJELATH ES, MURRAY J, RAHMAN S et al.: Novel vascular endothelial growth factor binding domains of fibronectin enhance vascular endothelial growth factor biological activity. Cir. Res. (2002) 19(1):25-31.
8. LEE S, JILANI SM, NIKOLOVA GV, CARPIZO D, IRUELA-ARISPE M: Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J. Cell Biol. (2005) 169(4):681-691.
9. 1 integrins. FASEB J. (2005) 15(8):1389-1397.
10. XU J, RODRIGUEZ D, KIM JJ, BROOKS PC: Generation of monoclonal antibodies to cryptic collagen sites by using subtractive immunization. Hybridoma. (2000) 19(5):375-385.
11. XU J, RODRIGUEZ D, PETITCLERC E et al.: Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo. J. Cell Biol. (2001) 154(5):1069-1079.
12. HANGAI M, KITAYA N, XU J et al.: Matrix metalloproteinase-9-dependent exposure of a cryptic migratory control site in collagen is required before retinal angiogenesis. Am. J. Pathol. (2002) 161(4):1429-1437.
13. FOX SB, GATTER KC, HARRIS AL: Tumor angiogenesis. J. Pathol. (1996) 179(3):232-237.
14. WANG T, WARD Y, TIAN L et al.: CD97, an adhesion receptor on inflammatory cells, stimulates angiogenesis through binding integrin counterreceptors on endothelial cells. Blood (2005) 105(7):2836-2844.
15. BETSHOLTZ C, LINDBLOM P, GERHARDT H: Role of pericytes in vascular morphogenesis. EXS. (2005) 94:115-125.
16. WARY KK, MAINIERO F, ISAKOFF SJ, MARCANTIO EE, GIANCOTTI FG: The adaptor protein Shc couples a class of integrins to the control the cell cycle progression. Cell (1996) 87(4):733-743.
17. 3. Cell (1996) 85(5):683-693.
18. BROOKS PC, SILLETTI S, VON SCHALSHA TL, FRIEDLANDER M, CHERESH DA: Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity. Cell (1998) 92(3):391-400.
19. RUNDHAUG JE: Matrix metalloproteinases and angiogenesis. J. Cell. Mol. Med. (2005) 9(2):267-285.
20. 1. Mol. Biol. Cell. (2001) 12(10):2975-2986.
21. V integrin on the surface of human NK cells. Biochem. Biophys. Res. Commun. (2004) 315(4):1025-1032.
22. 1 integrin conformation and function by urokinase receptor binding. J. Cell Biol. (2005) 168(3):501-511.
23. DAVIS GE, BAYLESS KJ, MAVILA A: Molecular basis of endothelial cell morphogenesis in three-dimensional extracellular matrices. Anat. Rec. (2002) 268(3):252-275.
24. BROOKS PC: Cell adhesion molecules in angiogenesis. Cancer Met. Rev. (1996) 15(2):187-194.
25. FFRENCH-CONSTANT C, COLOGNATO H: Integrins: versatile integrators of extracellular signals. Trend Cell. Biol. (2004) 14(12):678-686.
26. HYNES RO: Integrins: bidirectional, allosteric signaling machines. Cell (2002) 110(6):673-687.
27. ARNAOUT MA: Integrin structure: new twists and turns in dynamic cell adhesion. Immunol. Rev. (2002) 186:125-140.
28. 3 in a complex with fibronectin. J. Cell Biol. (2005) 168(7):1109-1118.
29. SHIMAOKA M, SPRINGER TA: Therapeutic antagonists and conformational regulation of integrin function. Nat. Rev. Drug Dis. (2003) 2(9):703-716.
30. 3. Science. (2001) 294(5541):339-345.
31. XIONG JP, STEHLE T, GOODMAN SL, ARNAOUT MA: Integrins, cations and ligands: making the connection. J. Thromb. Haemost. (2003) 1(7):1642-1654.
32. GRASHOFF C, THIEVESSEN I, LORENZ K, USSAR S, FASSLER R: Integrin-linked kinase: integrin's mysterious partner. Curr. Opin. Cell Biol. (2004) 16(5):565-571.
33. CRITCHLEY DR: Cytoskeletal proteins talin and vinculin in integrin-mediated adhesion. Biochem. Soc. Trans. (2004) 32(Part 5):831-836.
34. PETITCLERC E, BOUTAUD A, PRESTAYKO A et al.: New functions for non-collagenous domains of human collagen type IV. Novel integrin ligands inhibiting angiogenesis and tumor growth in vivo. J. Biol. Chem. (2000) 275(11):8051-8061.
35. KALLLURY R: Basement membranes: structure, assembly and role in tumor angiogenesis. Nat. Rev. Cancer. (2003) 3(6):422-433.
36. NYBERG P, XIE L, KALLURI R: Endogenous inhibitors of angiogenesis. Cancer Res. (2005) 65(10):3967-3979.
37. BIX G, IOZZO RV: Matrix revolutions: 'tails' of basement-membrane components with angiostatic functions. Trends Cell Biol. (2005) 15(1):52-60.
38. SAGE EH, REED M, FUNK SE et al.: Cleavage of the matricellular protein SPARC by matrix metalloproteinase 3 produces polypeptides that influence angiogenesis. J. Biol. Chem. (2003) 278(39):849-857.
39. ZHONG J, ELICEIRI B, STUPACK D et al.: Neovascularization of ischemic tissues by gene delivery of the extracellular matrix protein Del-1. J. Clin. Invest. (2003) 112(1):30-41.
40. 3 mRNA down-regulate expression of the targeted integrins and inhibit endothelial cell capillary tube formation in fibrin and matrigel. J. Biol. Chem. (2002) 277(9):6779-6787.
41. 2 subunit on endothelium. Cancer Res. (2002) 62(21):6116-6123.
42. SERINI G, VALDEMBRI D, ZANIVAN S et al.: Class 3 semaphorins control vascular morphogenesis by inhibiting integrin function. Nature (2003) 424(6947):391-397.
43. PATEL SR, JENKINS J, PAPADOPOLOUS N et al.: Pilot study of vitaxin-an angiogenesis inhibitor-in patients with advanced leiomyosarcomas. Cancer (2001) 92(5):1347-1348.
44. TRIKHA M, ZHOU Z, NEMETH JA et al.: CNTO 95, a fully human monoclonal antibody that inhibits αv integrins, has antitumor and antiangiogenic activity in vivo. Int. J. Cancer. (2004) 110(3):326-335.
45. 1 antibody promotes cell death in proliferating endothelial cells. American Association for Cancer Research, Phoenix, USA (2003).
46. 7 integrin antagonist after oral administration at single and multiple once-daily ascending doses in healthy volunteers. J. Clin. Pharmacol. (2004) 44(12):1368-1378.
47. 1 knockout mice cause reduced tumor vascularization. Proc. Natl. Acad. Sci. USA (2000) 97(5):2202-2207.
48. GUSTAFASSON E, FASSLER R: Insight into extracellular matrix functions from mutant mouse models. Exp. Cell Res. (2000) 261:52-68.
49. 1 integrins. Proc. Natl. Acad. Sci. USA (1997) 94(25):13612-13617.
50. 1 integrin in vitro and angiogenesis in vivo. Cancer Res. (2003) 63(9):2020-2023.
51. 1 integrin. J. Cell Biol. (2004) 166(1):97-109.
52. 1 integrin. Curr. Opin. Cell Biol. (2000) 12(5):548-553.
53. 1 integrin modulates endothelial cell responses to thrombospondin-1. Mol. Biol. Cell. (2000) 11(9):2885-2900.
54. 1 integrins. J. Cell Biol. (2005) 168(4):643-653.
55. WEIDLE UH, KONIG B: Urokinase receptor antagonists: novel agents for the treatment of cancer. Expert. Opin. Investig. Drugs. (1998) 7(3):391-403.
56. SEO DW, LI H, GUEDEZ L et al.: TIMP-2 mediated inhibition of angiogenesis: an MMP-independent mechanism. Cell. (2003) 114(2):171-180.
57. 5-integrin-negative teratocarcinomas and embryoid bodies. Cancer Res. (2001) 61(13):5255-5261.
58. 4 integrins are essential in placental and cardiac development. Development (1995) 121(2):549-560.
59. 1 integrin mediates selective endothelial cell responses to thrombospondins 1 and 2 in vitro and modulates angiogenesis in vivo. Circ. Res. (2004) 94(4):462-470.
60. 4 integrins. J. Immunol. (2003) 170(11):5704-5711.
61. 1 integrin on blood vessels in tumors. Am. J. Pathol. (2005) 167(1):193-211.
62. 2+/calmodulin-dependent protein kinase IV. J. Cell Biochem. (2005) 95(6):1214-1223.
63. 1 with the central cell-binding domain of fibronectin. Am. J. Pathol. (2000) 156(4):1345-1362.
64. SCHUCH G, HEYMACH JV, NOMI M et al.: Endostatin inhibits the vascular endothelial growth factor-induced mobilization of endothelial progenitor cells. Cancer Res. (2003) 63(23):8345-8350.
65. HANAI J, GLOY J, KARUMANCHI SA et al.: Endostatin is a potential inhibitor of Wnt signaling. J. Cell Biol. (2002) 158(3):529-539.
66. 1 and protein kinase A. J. Biol. Chem. (2000) 275(43):33920-33928.
67. GRANT DS, KLEINMAN HK: Regulation of capillary formation by laminin and other components of the extracellular matrix. EXS (1997) 79:317-333.
68. 4 integrin is negatively regulated during angiogenesis. J. Cell Sci. (2003) 116(Part 18):3771-3781.
69. 4 integrin. Semin. Cancer Biol. (2004) 14(2):115-122.
70. 4 signaling promotes tumor angiogenesis. Cancer Cell (2004) 6(5):471-483.
71. BAR-SHAVIT R, GINZBURG Y, MAOZ M, VLODAVSKY I, PERETZ T: The involvement of thrombin RGD in metastasis: characterization of a cryptic adhesive site. Isr. J. Med. Sci. (1995) 31(2-3) 86-94.
72. OSSOWSKI L, AGUIRRE-GHISO JA: Urokinase receptor and integrin partnership: coordination of signaling for cell adhesion, migration and growth. Curr. Opin. Cell Biol. (2000) 12(5): 613-620.
73. 3-integrin and activating VEGF-R2. Microvasc. Res. (2004) 68(3):169-178.
74. DE S, RAZORENOVA O, McCABE NP, O'TOOLE T, QIN J, BYZOVA TV: VEGF-integrin interplay controls tumor growth and vascularization. Proc. Natl. Acad. Sci. USA (2005) 102(21):7589-7594.
75. 3 integrin linked signaling pathways: cellular responses to changes in multiple signaling inputs. Mol. Endocrinol. (2005) 19(1):1-11.
76. SCHNELLER M: Identification of a candidate integrin-fraction associated with the activated form of the PDGF-receptor. Biochem. Biophys. Res. Commun. (2001) 281(2):595-602.
77. BRIGSTOCK DR: Regulation of angiogenesis and endothelial cell function by connective tissue growth factor (CTGF) and cysteine-rich 61 (CYR61). Angiogenesis (2002) 5(3):153-165.
78. 3 contains a cell surface receptor site for thyroid hormone that is linked to activation of mitogen-activated protein kinase and induction of angiogenesis. Endocrinology (2005) 146(7):2864-2871.
79. YI M, RUOSLAHTI E: A fibronectin fragment inhibits tumor growth, angiogenesis and metastasis. Proc. Natl. Acad. Sci. USA (2001) 98(2):620-624.
80. 3 integrin. Cancer Res. (2005) 65(10):4153-4161.
81. 5 integrin antagonists inhibit angiogenesis in vitro. Angiogenesis (2003) 6(2):105-119.
82. 5 to promote tumor cell dissemination in vivo. J. Clin. Invest. (1997) 99(6):1390-1398.
83. v integrins. Science (1995) 270(5241):1500-1502.
84. v integrin-mediated Ras-ERK signaling during two pathways of angiogenesis. J. Cell Biol. (2003) 162(5):933-943.
85. ALAVI A, HOOD JD, FRAUSTO R, STUPACK DG, CHERESH DA: Role of Raf in vascular protection from distinct apoptotic stimuli. Science (2003) 301(5629):94-96.
86. 5 integrin. Exp. Cell Res. (2004) 294(1):172-184.
87. 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell (1994) 79(7):1157-1164.
88. 3 rescues melanoma cells from apoptosis in three-dimensional dermal collagen. Proc. Natl. Acad. Sci. USA (1994) 91(19):8856-8860.
89. 3 promotes M21 melanoma growth in human skin by regulating tumor cell survival. Cancer Res. (1999) 59(11):2724-2730.
90. 3 during angiogenesis. J. Clin. Invest. (1996) 98(2):426-433.
91. v-integrin function in retinal neovascularization. J. Biol. Chem. (2002) 277(16):13371-13374
92. STUPACK DG, PUENTE XS, BOUTSABOUALOY S, STORGARD CM, CHERESH DA: Apoptosis of adherent cells by recruitment of caspase-8 to unligated integrins. J. Cell Biol. (2001) 155(3):459-470
93. 3-integrin-deficient mice. Cancer Res. 64(23):8643-8650
94. RAWLINGS NG, SIMKO E, BEBCHUK T, CALDWELL SJ, SINGH B: Localization of integrin α(v)β3 and vascular endothelial growth factor receptor-2 (KDR/Flk-1) in cutaneous and oral melanomas of dog. Histol. Histopathol. (2003) 18(3):819-826.
95. HUTCHINGS H, ORTEGA N, PLOUET J: Extracellular matrix-bound vascular endothelial growth factor promotes endothelial cell adhesion, migration, and survival through integrin ligation. FASEB (2003) 17(11):1520-1522.
96. 3 by an organic molecule inhibits angiogenesis and tumor growth in vivo. Proc. Natl. Acad. Sci. USA (2001) 98(1):119-124.
97. HOOD JD, BEDNARSKI M, FRAUSTO R et al.: Tumor regression by targeted gene delivery to the neovasculature. Science (2002) 296(5577):2404-2407.
98. CHEN X, PLASENCIA C, HOU Y, NEAMATI N: Synthesis and biological evaluation of dimeric RGD peptide-paclitaxel conjugated as a model for integrin-targeted drug delivery, J. Med. Chem. (2005) 48(4):1098-1106.
99. GIANNELLI G, FALK-MARZILLIER J, SCHIRALDI O, STETLER-STEVENSON WG, QUARANTA V: Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5. Science (1997) 277(5323):225-228.
100. KIYOSHIMA K, ODA Y, KINUKAWA N, NAITO S, TSUNEYOSHI M: Overexpression of laminin-5 γ-2 chain and its prognostic significance in urothelial carcinoma of urinary bladder: association with expression of cyclooxygenase 2, epidermal growth factor, and human epidermal growth factor 2. Hum. Pathol. (2005) 36(5):522-530.
101. EBBINGHAUS C, SCHEUERMANN J, NERI D, ELIA G: Diagnostic and therapeutic applications of recombinant antibodies: targeting the extra-domain B of fibronectin, a marker of tumor angiogenesis. Curr. Pharm. Des. (2004) 10(13):1537-1549.